Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Corticosteroid
synthetic glucocorticoid |
| gptkbp:ATCCode |
R03BA05
R01AD08 |
| gptkbp:bioavailability |
10-30% (inhaled)
less than 1% (oral) |
| gptkbp:brand |
gptkb:Cutivate
gptkb:Flixotide gptkb:Flonase gptkb:Veramyst gptkb:Flovent |
| gptkbp:CASNumber |
80474-14-2
|
| gptkbp:chemicalClass |
corticosteroid ester
|
| gptkbp:contraindication |
hypersensitivity
untreated local infection |
| gptkbp:discoveredBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
7.8 hours
|
| gptkbp:hasMolecularFormula |
C25H31F3O5S
|
| https://www.w3.org/2000/01/rdf-schema#label |
fluticasone propionate
|
| gptkbp:introducedIn |
1990
|
| gptkbp:KEGGID |
D00357
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
glucocorticoid receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:proteinBinding |
91%
|
| gptkbp:PubChem_CID |
39137
444036 CHEMBL1200698 DB00588 |
| gptkbp:riskFactor |
adrenal suppression (with high doses)
growth suppression in children (rare) systemic corticosteroid effects (rare) |
| gptkbp:routeOfAdministration |
topical
inhalation nasal spray |
| gptkbp:sideEffect |
gptkb:oral_candidiasis
headache hoarseness throat irritation nosebleed |
| gptkbp:UNII |
0J48LPH2TH
|
| gptkbp:usedFor |
asthma
chronic obstructive pulmonary disease allergic rhinitis nasal polyps |
| gptkbp:bfsParent |
gptkb:fluticasone
|
| gptkbp:bfsLayer |
6
|